source
- Labcorp reports Q2 sales of $3.73 billion, lifts full-year revenue outlook despite missing consensusLabcorp announced second‑quarter revenue of $3.73 billion, up from $3.53 billion a year earlier, driven by strong performance across its core businesses. The Diagnostics division grew 5.5% to $2.9…
- MapLight shares tumble over 60% after mixed Phase 2 schizophrenia trial resultsMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the experimental schizophrenia drug ML-007C-MA, causing its stock to fall sharply. The trial enrolled 307 patients wi…